ProMIS Neurosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

NET LOSS PER SHARE (Tables)

NET LOSS PER SHARE (Tables)

6 Months Ended

Jun. 30, 2024

NET LOSS PER SHARE

Summary of computation of basic and diluted net loss per share attributable to common shareholders


		Three Months Ended June 30,						Six Months Ended June 30,
		2024			2023			2024			2023
Numerator:
Net loss attributable to common shareholders		$	(2,623,657)		$	(2,311,974)		$	(6,258,745)		$	(7,271,405)
Denominator:
Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders, basic and diluted			19,770,739			8,579,284			19,544,908			8,579,284
Net loss per share attributable to common shareholders, basic and diluted		$	(0.13)		$	(0.27)		$	(0.32)		$	(0.85)

Summary of outstanding potentially dilutive common shares equivalents were excluded from the computation of diluted net loss per share


		June 30,
		2024		2023
Options issued and outstanding under stock option plan		1,087,493		1,043,025
Warrants		12,793,270		1,873,622
Series 1 Convertible Preferred Shares		—		1,166,667
Series 2 Convertible Preferred Shares		1,166,667		—
Deferred Share Units		1,061		1,061
Total		15,048,491		4,084,375